Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Type 2 Diabetes Inadequately Controlled With Diet and Exercise
NCT06650007Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06650007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650007.